TABLE 2.
Baseline characteristics of participants by randomization sequence (either LGIP first and HGIP second or HGIP first and LGIP second) data are means and SE
| Male/female | Age (y) | Height (cm) | Weight (kg) | BMI (kg/m2) | HbA1c | Medication1/ Diet treatment | |
|---|---|---|---|---|---|---|---|
| LGIP first (n = 12) | 8/4 | 57 (2) | 175 (3) | 87 (6) | 28.3 (1) | 58 (6) | 10/2 |
| HGIP first (n = 13) | 9/5 | 56 (2) | 173 (2) | 98 (5) | 32.6 (1) | 61 (6) | 11/2 |
LGIP, low GI profile; HGIP, high GI profile. 1Includes metformin (n = 19), gliclazide (n = 6), dapagliflozin (n = 5), alogliptin (n = 2), and empagliflozin (n = 2).